DNGR-1-mediated cross-presentation of dead cell-associated antigens.
Adaptive immunity
Anti-tumour immunity
Anti-viral immunity
CD8(+) T cells
Cross-presentation
Cross-priming
DNGR-1/CLEC9A
Dendritic cells
Journal
Seminars in immunology
ISSN: 1096-3618
Titre abrégé: Semin Immunol
Pays: England
ID NLM: 9009458
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
28
11
2022
revised:
26
01
2023
accepted:
27
01
2023
pubmed:
10
2
2023
medline:
21
3
2023
entrez:
9
2
2023
Statut:
ppublish
Résumé
Conventional dendritic cells type 1 (cDC1) are critical for inducing protective CD8
Identifiants
pubmed: 36758378
pii: S1044-5323(23)00017-9
doi: 10.1016/j.smim.2023.101726
pii:
doi:
Substances chimiques
Receptors, Immunologic
0
Antigens
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101726Subventions
Organisme : Cancer Research UK
ID : CC2090
Pays : United Kingdom
Organisme : Medical Research Council
ID : CC2090
Pays : United Kingdom
Organisme : Wellcome Trust
ID : CC2090
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT223136/Z/21/Z
Pays : United Kingdom
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest C.R.S. is a founder of Adendra Therapeutics and owns stock options and/or is a paid consultant for Adendra Therapeutics, Bicara Therapeutics, Montis Biosciences, Bicycle Therapeutics and Sosei Heptares. C.R.S. has an additional appointment as a Visiting Professor in the Faculty of Medicine at Imperial College London and holds honorary professorships at University College London and King’s College London.